ZJOFHC(600120)
Search documents
浙江东方金融控股集团股份有限公司关于召开2025年度半年度业绩说明会的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-16 02:11
Core Points - The company will hold a half-year performance briefing on September 19, 2025, from 15:00 to 16:00 [2][3] - The briefing aims to provide investors with a comprehensive understanding of the company's operational performance, financial status, and development strategy [2] - Investors can submit questions before the briefing through a designated website or WeChat mini-program [4] Meeting Details - The meeting will take place online at "Value Online" [3][5] - Key participants include the company's chairman and general manager, independent directors, board secretary, and financial head [3] - Investors can join the interactive session via a specific URL or WeChat mini-program on the day of the event [4] Contact Information - Contact person for inquiries is Ji Feng, with a provided phone number and email address for further communication [4]
浙江东方(600120) - 浙江东方金融控股集团股份有限公司关于召开2025年度半年度业绩说明会的公告
2025-09-15 07:45
| 股票代码:600120 | 证券简称:浙江东方 | | | 编号:2025-050 | | --- | --- | --- | --- | --- | | 债券代码:138898.SH | 债券简称:23 | 东方 | 01 | | | 债券代码:240620.SH | 债券简称:24 | 东方 | 01 | | | 债券代码:241264.SH | 债券简称:24 | 东方 | K1 | | | 债券代码:241781.SH | 债券简称:24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 关于召开 2025 年度半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 会 议 问 题 征 集 : 投 资 者 可 于 2025 年 9 月 19 日 前 访 问 网 址 https://eseb.cn/1rAedyrbIZO 或使用微信扫描下方小程序码进行会前提问,公司将 通过本次业绩说明会,在信息披露允许范围内就投资者普遍关注的问题进行回答。 一、说明会类型 浙江东方金融控股 ...
期货概念板块9月10日跌0.14%,苏豪时尚领跌,主力资金净流出3.8亿元
Sou Hu Cai Jing· 2025-09-10 08:58
Market Overview - The futures concept sector experienced a decline of 0.14% compared to the previous trading day, with Suhao Fashion leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers in the futures concept sector included: - Yuanda Environmental (600292) with a closing price of 13.50, up 6.13%, and a trading volume of 451,800 shares, totaling 608 million yuan [1] - Quzhou Development (600208) closed at 4.53, up 1.57%, with a trading volume of 926,400 shares, totaling 418 million yuan [1] - Xinda Securities (601059) closed at 18.82, up 1.29%, with a trading volume of 409,000 shares, totaling 773 million yuan [1] - Conversely, significant decliners included: - Shisuo Fashion (600287) closed at 6.09, down 2.40%, with a trading volume of 83,700 shares, totaling 51.23 million yuan [2] - Meihu Co. (603319) closed at 37.57, down 2.39%, with a trading volume of 134,400 shares, totaling 510 million yuan [2] - Zhongke Jincai (002657) closed at 35.80, down 1.57%, with a trading volume of 303,400 shares, totaling 1.104 billion yuan [2] Capital Flow - The futures concept sector saw a net outflow of 380 million yuan from main funds, while retail funds experienced a net inflow of 269 million yuan [2] - The main fund inflows for notable stocks included: - Xinda Securities (601059) with a net inflow of 47.42 million yuan, accounting for 6.14% of total inflows [3] - Yuanda Environmental (600292) with a net inflow of 45.33 million yuan, accounting for 7.45% of total inflows [3] - In contrast, significant outflows were observed in: - Yuanda Environmental (600292) with a net outflow of 51.45 million yuan from retail investors, accounting for -6.66% [3] - Dahuang Technology (600288) with a net outflow of 72.80 million yuan from retail investors, accounting for -22.97% [3]
浙江东方基因生物制品股份有限公司关于独立董事辞职的公告
Shang Hai Zheng Quan Bao· 2025-09-09 21:08
Group 1 - The independent director Li Bo has resigned from his position due to personal work reasons, which will not affect the board's minimum member requirements or its normal operations [1][2] - The company expresses gratitude for Li Bo's contributions during his tenure, highlighting his adherence to independent, objective, and prudent principles [2] Group 2 - The company’s subsidiary Healgen Scientific LLC and its holding subsidiary Hangzhou Laihe Biotechnology Co., Ltd. have recently obtained medical device registration certificates for several products [4] - The registration of respiratory joint testing reagents in domestic and international markets enhances the company's product offerings and aids in addressing seasonal respiratory infections [5] - The certification of the fully automatic biochemical analyzer and related freeze-dried biochemical reagents in Peru expands the company's product range in the South American market, supporting the detection of various diseases [5]
浙江东方金融控股集团股份有限公司 关于为下属公司提供担保的进展公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-08 23:28
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 ● 被担保人名称: 1、东方嘉富人寿保险有限公司(简称"东方嘉富人寿") 2、浙江济海贸易发展有限公司(简称"浙江济海") 3、浙江东方集团供应链管理有限公司(简称"东方供应链") 4、舟山济海能源有限公司(简称"舟山济海") 5、浙江东方乾睿贸易发展有限公司(简称"东方乾睿") ● 风险提示:本次被担保人中,东方嘉富人寿、浙江济海、东方供应链、舟山济海、济桐贸易、东方乾 睿、东方嘉信的资产负债率超过70%,提醒投资者充分关注担保风险。 一、担保情况概述 为支持下属公司业务发展,促进2025年度经营目标的达成,浙江东方金融控股集团股份有限公司(以下 简称"公司"或"浙江东方")于2025年4月23日、6月22日召开十届董事会第十一次会议、2024年年度股东 大会,审议通过了《关于公司2025年度为下属公司提供额度担保的议案》,同意公司为下属公司提供合 计最高额度为451,500万元的额度担保。具体情况见公司2025年4月25日发布的《浙江东方金融控股集团 股份有限公司关于2025 ...
浙江东方(600120) - 浙江东方金融控股集团股份有限公司关于为下属公司提供担保的进展公告
2025-09-08 10:00
| 股票代码:600120 | 证券简称:浙江东方 | | | 编号:2025-049 | | --- | --- | --- | --- | --- | | 债券代码:138898.SH | 债券简称:23 | 东方 | 01 | | | 债券代码:240620.SH | 债券简称:24 | 东方 | 01 | | | 债券代码:241264.SH | 债券简称:24 | 东方 | K1 | | | 债券代码:241781.SH | 债券简称:24 | 东方 | 03 | | 浙江东方金融控股集团股份有限公司 关于为下属公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 ● 被担保人名称: 1、东方嘉富人寿保险有限公司(简称"东方嘉富人寿") 2、浙江济海贸易发展有限公司(简称"浙江济海") ● 本期担保金额及担保余额情况:2025年8月,公司对下属公司提供的担保 累计发生额为34,688.48万元,截至2025年8月31日,公司对下属公司的担保余额 合计为301,677.77万元,占公司2024年度经审 ...
浙江东方: 浙江东方金融控股集团股份有限公司关于收购杭州联合农村商业银行股份有限公司部分股份暨关联交易的结果公告
Zheng Quan Zhi Xing· 2025-08-29 11:44
Core Viewpoint - Zhejiang Oriental Financial Holding Group Co., Ltd. has completed the acquisition of shares in Hangzhou United Rural Commercial Bank, which is a related party transaction involving a total investment of approximately 140 million RMB [1][2][3]. Transaction Overview - The company and its controlling shareholder, Zhejiang International Trade Group Co., Ltd., acquired 0.6970% and 5.9319% of Hangzhou United Bank's shares at a price of 9.7 RMB per share, totaling 14,741.86 million RMB and 125,463.08 million RMB respectively [1][2]. - The total shares acquired by the company amount to 15,197,790 shares, representing a total of 6.7570% of the bank's shares [2][3]. Transaction Progress - The acquisition has received approval from the Zhejiang Regulatory Bureau of the National Financial Supervision Administration, and the ownership transfer process has been completed as of the announcement date [2][3]. Impact on the Company - The acquisition price is below the fair value of the identifiable net assets of Hangzhou United Bank, leading to an expected non-recurring gain of approximately 130 million RMB for the current fiscal year [2][3]. - Following the acquisition, the company holds a total of 3.94% of Hangzhou United Bank's shares, aiming to enhance its financial business development and overall competitiveness through this partnership [4].
浙江东方(600120) - 浙江东方金融控股集团股份有限公司关于收购杭州联合农村商业银行股份有限公司部分股份暨关联交易的结果公告
2025-08-29 11:28
浙江东方金融控股集团股份有限公司 关于收购杭州联合农村商业银行股份有限公司部分股份 暨关联交易的结果公告 | 股票代码:600120 | 证券简称:浙江东方 | | | 编号:2025-048 | | --- | --- | --- | --- | --- | | 债券代码:138898.SH | 债券简称:23 | 东方 | 01 | | | 债券代码:240620.SH | 债券简称:24 | 东方 | 01 | | | 债券代码:241264.SH | 债券简称:24 | 东方 | K1 | | | 债券代码:241781.SH | 债券简称:24 | 东方 | 03 | | 二、交易进展情况 2025年6月,公司、省国贸集团分别与转让方厦门创举签署股份转让协议, 省国贸集团与转让方福信集团签署股份转让协议。本次股份转让的每股转让价格 为人民币9.7元。交易股份数及金额具体如下: 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要事项提示 ● 浙江东方金融控股集团股份有限公司(以下简称"公司")与控股股东 浙江省国际贸 ...
浙江东方基因生物制品股份有限公司2025年半年度报告摘要
Shang Hai Zheng Quan Bao· 2025-08-29 05:10
Group 1 - The company has been expanding its domestic and international production capacity, sales networks, and product lines through acquisitions and new projects, which has led to increased management, research and development, and sales expenses, impacting short-term operating performance [1][3][4] - The company faces potential risks of losses in overall operating performance by 2025 due to high costs associated with new projects and acquisitions [3][4] - The company is actively responding to global tariff changes that may affect its export business, particularly in the US and Europe, by optimizing market layouts and reducing product costs [3][4] Group 2 - The company is involved in a significant contract dispute in the US, which has not yet impacted its 2025 financial results, and it is taking legal action to protect its interests [3][4][5] - The company has submitted a defense in the ongoing lawsuit and has temporarily withdrawn a related civil suit in China while retaining the right to pursue it later [4][5][6] Group 3 - The company plans to hold a half-year performance briefing on September 11, 2025, to address investor concerns and provide insights into its financial status [7][8][9] - The company will also hold its first extraordinary general meeting of 2025 on September 15, 2025, to discuss various resolutions, including the cancellation of the supervisory board [14][15][16] Group 4 - The company reported a total fundraising amount of 637.5 million yuan from its initial public offering, with a net amount of 550.82 million yuan after expenses [37][38] - As of June 30, 2025, the company has utilized 10.11 million yuan of the raised funds for investment projects, with a remaining balance of 61.85 million yuan [38][41]
浙江东方基因生物制品股份有限公司

Shang Hai Zheng Quan Bao· 2025-08-29 05:10
Core Points - The company announced the resignation of Mr. Fang Xincheng from the board of directors and the audit committee due to personal reasons [1] - The resignation will not affect the minimum number of directors required by law and will not disrupt the normal operation of the board [1] - The company expressed gratitude for Mr. Fang's contributions during his tenure [1] Summary by Sections Resignation Announcement - Mr. Fang Xincheng submitted a written resignation report to the board [1] - His resignation is effective immediately upon delivery to the board [1] Impact on Company Operations - The resignation will not lead to a decrease in the number of directors below the legal minimum [1] - The normal functioning of the board will remain unaffected [1] Acknowledgment of Contributions - The company and the board expressed sincere thanks for Mr. Fang's diligent work and contributions to the company's development [1]